Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Position Trimmed by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 36.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 760,469 shares of the company’s stock after selling 444,525 shares during the period. Assenagon Asset Management S.A.’s holdings in Amneal Pharmaceuticals were worth $6,023,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after acquiring an additional 777,568 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after purchasing an additional 641,405 shares in the last quarter. BlackBarn Capital Partners LP lifted its holdings in Amneal Pharmaceuticals by 41.5% in the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after purchasing an additional 586,703 shares during the period. Geode Capital Management LLC grew its position in Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after buying an additional 378,136 shares in the last quarter. Finally, Polar Asset Management Partners Inc. increased its stake in Amneal Pharmaceuticals by 122.5% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company’s stock valued at $3,270,000 after buying an additional 216,400 shares during the period. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 0.6 %

NASDAQ AMRX opened at $8.26 on Monday. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The firm’s fifty day simple moving average is $8.18 and its 200-day simple moving average is $8.12. The company has a market capitalization of $2.56 billion, a PE ratio of -12.15 and a beta of 1.10.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on AMRX shares. Truist Financial raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Insiders Place Their Bets

In other news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gautam Patel sold 17,410 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the sale, the director now owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 123,657 shares of company stock valued at $1,016,687 over the last quarter. Insiders own 17.46% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.